MedTrace Logo

BAC in Patient With Alzheimer's Disease or Vascular Dementia

NCT02467413 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2026-05-20

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of BAC patients with Alzheimer's disease or vascular dementia.The secondary objective of this study is to evaluate the safety of BAC patients with Alzheimer's disease or vascular dementia.

Conditions

Interventions

DRUG

BAC

(vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)

OTHER

BAC Matched Vehicle

BAC Matched Vehicle

Sponsors & Collaborators

  • A2 Healthcare Taiwan Corporation

    collaborator INDUSTRY

  • Botanicure Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Pai Ming-Chyi, PhD · Neurology National Cheng Kung University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-30
Primary Completion
2018-11-01
Completion
2018-11-01
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02467413 on ClinicalTrials.gov